Blood Products Market Size, Share & Trends Analysis Report By Product Type (Whole Blood, Red Blood Cells (RBCs), White Blood Cells, Platelets, Plasma, Others), By Application (Anemia, Hemophilia, Surgical Procedures, Trauma and Accident Care, Cancer Treatment, Immunodeficiency Diseases, Others), By End User (Hospitals, Blood Banks, Diagnostic Laboratories, Ambulatory Surgical Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Blood Products Market Size

The global blood products market size was valued at USD 37.12 billion in 2024 and is estimated to grow from USD 38.79 billion in 2025 to reach USD 55.16 billion by 2033, growing at a CAGR of 4.50% during the forecast period (2025–2033).

The global blood products market is propelled by several significant factors. The rising volume of surgical procedures and trauma cases worldwide is driving an increased demand for blood transfusions, which are crucial for patient survival and recovery. Government initiatives promoting voluntary blood donation and stricter blood safety regulations have enhanced the availability and quality of safe blood products, further supporting market expansion.

Additionally, the aging population is a key contributor, as older individuals often require more transfusion therapies due to chronic illnesses like anemia and cardiovascular diseases. Moreover, the growing use of plasma-derived therapies for treating immune deficiencies and neurological disorders is expanding the market’s scope. These therapies are increasingly recognized for their effectiveness in managing complex conditions. Collectively, these factors create a robust and sustained demand for blood products, underscoring the market’s vital role within global healthcare systems.

Current Market Trends

Shift toward automated blood collection and processing systems

One of the key trends shaping the global blood products market is the increasing shift toward automated blood collection and processing systems. Automation enhances efficiency, reduces human error, and improves the overall safety and quality of blood products. These systems also support higher throughput, which is essential for meeting the rising demand for blood components in hospitals and diagnostic centres.

• For instance, in October 2024, Terumo Blood and Cell Technologies introduced the Reveos™ Automated Blood Processing System in the U.S., marking the first whole blood automation device approved by the FDA. This system streamlines the separation of whole blood into components—platelets, plasma, and red blood cells—in a single centrifugation cycle, reducing manual steps by up to 65% and enhancing operational efficiency.

As healthcare providers seek scalable and reliable solutions, the adoption of such automated systems is expected to accelerate globally.

Blood Products Market Growth Factors

Growing prevalence of blood-related disorders

The surging prevalence of blood-related disorders such as hemophilia, anemia, and leukemia is a significant driver for the global market. These conditions often need regular blood transfusions and specialized blood components for effective treatment, thereby boosting demand.

• According to the World Federation of Hemophilia, the global number of diagnosed hemophilia cases has risen significantly, with over 347,000 individuals affected in 2023.
• Furthermore, a recent study published in The Lancet estimates that anemia impacts approximately 24.3% of the world’s population, amounting to nearly 1.92 billion people.
• In addition, the Leukemia & Lymphoma Society reported that more than 60,000 new leukemia cases were diagnosed in the United States in 2023 alone.

These alarming statistics underline the growing patient pool dependent on blood products and related therapies worldwide.

Market Restraint

Limited shelf life of blood components,

The limited shelf life of blood components poses a significant restraint to the global blood products market. Different blood products have varying expiration periods—red blood cells typically last around 42 days, platelets only about 5 to 7 days, and plasma requires freezing to extend usability. This short shelf life creates challenges in inventory management, leading to wastage if products are not used in time.

Additionally, it complicates the supply chain, especially in remote or underdeveloped regions where timely transportation is difficult. These limitations restrict the ability of healthcare providers to maintain adequate and safe blood supplies, increasing operational costs and sometimes causing shortages that affect patient care quality.

Market Opportunities

Development of synthetic blood and alternatives

The development of synthetic blood and alternatives offers a transformative solution to persistent supply shortages in the global blood products market. Traditional blood donation systems face limitations such as donor availability, risk of contamination, and storage constraints. Synthetic blood, designed to mimic the oxygen-carrying function of red blood cells, holds promise for emergency transfusions, battlefield medicine, and remote healthcare settings.

• For instance, in November 2024, researchers at the University of Nottingham developed a method to create 'biocooperative' materials from a patient's own blood. By mixing synthetic peptides with whole blood, they engineered regenerative materials capable of repairing bone in animal models. This approach could lead to personalized regenerative therapies.

Such innovations not only address clinical needs but also open avenues for tailored medical solutions, driving demand in both therapeutic and surgical applications.

Regional Insights

The North American market shows robust growth driven by advanced healthcare infrastructure and strong government support for blood donation programs. The high prevalence of chronic diseases and trauma cases fuels the demand for blood products. Technological advancements in blood screening and processing enhance product safety and efficiency. Additionally, well-established plasma fractionation industries and increased awareness about blood disorders contribute to market expansion. Continuous investments in research and development further stimulate innovation, enabling the region to maintain leadership in blood product availability and quality.

U.S. Blood Products Market Trends

• The US market is propelled by high demand for plasma-derived therapies and trauma care. The American Red Cross and plasma centers like Grifols play key roles in supply. Rising cases of hemophilia and immune disorders fuel plasma product use. Advanced technologies in pathogen screening and automated collection systems enhance safety and efficiency. Additionally, initiatives encouraging voluntary donations help maintain a stable blood supply across healthcare facilities.
• The Canadian market for blood products is driven by increasing blood transfusions in surgeries and rising chronic disease cases. Canadian Blood Services and Héma-Québec ensure safe blood supply through advanced screening and collection techniques. Government programs promote voluntary donations, addressing regional shortages. Innovations like pathogen reduction technology and plasma-derived therapies are expanding access and safety, supporting the growing demand in hospitals and specialty clinics nationwide.

Asia-Pacific Blood Products Market Trends

Asia Pacific exhibits rapid market growth fueled by expanding healthcare infrastructure and rising awareness about blood-related diseases. Increasing population and improving access to advanced medical treatments boost demand for blood components. The region focuses on developing voluntary blood donation programs and enhancing blood safety protocols. Rising investments in modern blood collection and processing technologies drive efficiency. Furthermore, growing government initiatives to support plasma fractionation and the increasing prevalence of chronic conditions contribute significantly to the market’s expansion in this region.

• India’s blood products market is expanding, driven by growing awareness and government programs promoting voluntary blood donations, such as the National Blood Policy. Rising cases of anemia and hemophilia increase demand for blood components and plasma products. Key players like Reliance Life Sciences are investing in plasma fractionation technologies, enhancing the availability of affordable plasma-derived medicines in both urban and rural healthcare sectors.
• China’s blood products market is rapidly growing due to increased healthcare spending and rising chronic disease cases. The government’s efforts to improve blood donation systems, such as the National Blood Donation Law, have strengthened supply chains. Companies like Shanghai RAAS Blood Products Co. are expanding plasma fractionation capacity, meeting the rising demand for plasma-derived therapies in immunology and hemophilia treatment.

Europe Blood Products Market Trends

Europe’s blood products industry benefits from stringent regulatory frameworks ensuring safety and quality, encouraging widespread adoption of plasma-derived therapies. Growing aging populations and increasing incidence of hematological disorders propel demand. The region witnesses investments in automated blood processing technologies and pathogen reduction systems. Collaborative initiatives among healthcare organizations strengthen blood donation drives, improving supply chains. Additionally, rising public awareness and government funding support ongoing market growth, making Europe a key region for blood product innovation and improved transfusion outcomes.

• Germany’s blood products market is driven by advanced healthcare infrastructure and strong regulatory frameworks ensuring blood safety. The country has a robust network of blood donation centers, such as the German Red Cross, supporting steady plasma and platelet supplies. Growing demand for surgeries and chronic disease management fuels the market. Additionally, Germany is investing in pathogen reduction technologies, enhancing product safety and increasing market growth opportunities.
• France’s blood products market benefits from a well-organized national blood service, Établissement Français du Sang (EFS), which ensures high-quality plasma collection and processing. The increasing prevalence of hemophilia and immunodeficiency disorders drives demand for plasma-derived therapies. France is also adopting innovative recombinant blood products and expanding research in synthetic blood alternatives, positioning the market for growth amid rising healthcare expenditure and aging population challenges.

Product Type Insights

The whole blood segment holds a significant share of the global market due to its widespread use in emergency care, surgeries, and trauma cases. It is the simplest form of transfusion, containing all blood components—red cells, white cells, plasma, and platelets—making it ideal for acute blood loss scenarios. Despite the growing use of separated components, whole blood remains vital in developing regions where blood processing infrastructure is limited. The demand is further supported by military applications, disaster response efforts, and rural healthcare centers. Continued reliance on whole blood, especially in low-resource settings, sustains this segment’s importance.

Application Insights

The anemia segment is a key application area in the blood products industry, driven by the high global prevalence of iron-deficiency anemia and chronic anemia linked to renal disorders and cancer therapies. Blood transfusions, particularly red blood cell concentrates, are commonly administered to manage moderate to severe anemia. The growing geriatric population, rising malnutrition in emerging countries, and increasing awareness of anemia-related health risks further boost demand. Advancements in diagnostic capabilities and treatment protocols are also expanding therapeutic use. As anemia continues to be a major public health concern, this segment is expected to remain a primary driver of market growth.

End-User Insights

Hospitals represent the largest end-user segment in the global market, accounting for substantial consumption due to surgical interventions, oncology treatments, emergency care, and chronic disease management. These facilities require a continuous and reliable supply of blood products to support inpatient and outpatient procedures. Advanced hospital infrastructure in developed regions allows for effective storage, testing, and transfusion of blood components. Moreover, the integration of specialized blood banks and transfusion departments enhances operational efficiency. The growing burden of diseases requiring blood-based therapies and the rise in hospital admissions globally further reinforce the dominance of this segment in the overall market.

Company Market Share

Leading companies in the blood products market are focusing on innovation through advanced blood processing technologies and expanding their product portfolios with recombinant and plasma-derived therapies. They are investing in research to improve the safety, efficacy, and shelf life of blood products. Strategic collaborations, mergers, and expanding their presence in emerging markets are key strategies to capture greater market share and address the growing global demand for safe and effective blood therapies.

Haemonetics Corporation: Haemonetics Corporation, founded in 1971 and headquartered in Boston, Massachusetts, is a global leader in blood and plasma management solutions. The company offers a comprehensive portfolio of medical devices and software, including automated plasma collection systems, hemostasis analyzers, and blood management software. Serving over 50 countries, Haemonetics plays a pivotal role in enhancing patient care and operational efficiency across blood centers and hospitals. With a reported revenue of $1.3 billion in fiscal year 2024, the company continues to innovate in transfusion medicine and surgical blood management.

• In January 2025, Haemonetics finalized the sale of its whole blood collection, processing, and filtration assets to GVS, S.p.A., a prominent manufacturer of healthcare filter solutions. The transaction, valued at up to $67.8 million (including $45.3 million upfront and up to $22.5 million in contingent earn-outs over the next four years), encompassed:

Recent Developments

• May 2025-The Landstuhl Regional Medical Center (LRMC) Blood Services Program collaborated with the 86th Aeromedical Evacuation Squadron at Ramstein Air Base, Germany, to supply both actual and simulated blood products for the Defender Europe 25 Exercise. This large-scale training event, organized by U.S. Army Europe and Africa, enabled Army and Air Force medical teams from LRMC and Ramstein to showcase their medical knowledge and operational capabilities.

• January 2025-VectorBuilder’s partner, Ucello, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its allogeneic CAR-T cell therapy, UC101, which targets CD19 and is derived from umbilical cord blood. VectorBuilder supported this clinical program by delivering fully customized, end-to-end CDMO solutions.
• November 2024- StemCyte Inc., a fully owned subsidiary of StemCyte International Ltd., announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its blood product REGENECYTE™, an essential cord blood stem cell therapy used for transplantation in patients suffering from blood and immune system disorders. This milestone makes StemCyte the 15th company to receive BLA approval in 2024 and marks it as the first U.S.-based commercial biotech firm to obtain a biologics license specifically for cord blood stem cell therapy.